New Test Predicts Potential Success of BCG Immunotherapy for Bladder Cancer
By LabMedica International staff writers Posted on 03 Sep 2018 |
Image: A micrograph showing granulomatous inflammation of bladder neck tissue due to Bacillus Calmette-Guérin (BCG) used to treat bladder cancer (Photo courtesy of Wikimedia Commons).
A laboratory test that measures the amount of IL2 secretion from CD4+ T cells after overnight in vitro incubation with tuberculin predicts the potential success of BCG (Bacille Calmette-Guérin) immunotherapy treatment for bladder cancer.
BCG is used in the treatment of superficial forms of bladder cancer. Since the late 1970s, evidence has become available that instillation of BCG into the bladder is an effective form of immunotherapy in this disease. While the mechanism is unclear, it appears a local immune reaction is mounted against the tumor. Immunotherapy with BCG prevents recurrence in up to 67% of cases of superficial bladder cancer. Thus, about 30% of patients experience treatment failure, which cannot be predicted in advance and carries a high risk of disease progression.
Investigators at Brighton and Sussex Medical School (United Kingdom) examined the in vitro tuberculin-responsiveness of CD4+ T cells before BCG immunotherapy in 42 patients with high-risk (non-muscle invasive bladder cancer) NMIBC. The frequencies and functionalities of cytokine-expressing CD4+ T cells immediately before and after BCG immunotherapy induction were assessed by flow cytometry after overnight tuberculin stimulation. Tuberculin-induced secreted mediators were measured by electrochemiluminescence. The results were correlated with recurrence-free patient survival six months after induction.
Results revealed that a tuberculin-induced, secreted, IL2 concentration higher than 250 picograms per milliliter was the best predictor of recurrence-free survival, providing 79% sensitivity, 86% specificity, and overall correct classification in 78.6% of cases. In 50% of patients later experiencing recurrence, but not in any of the recurrence-free survivors, IL2 secretion was less than 120 picograms per milliliter.
Senior author Dr. Florian Kern, professor of immunology at Brighton and Sussex Medical School, said, "The simplicity of our new test makes it very attractive as a clinical test. There are several tests for tuberculosis that are ultimately based on the same test principle and have been rolled out across the world in recent times."
The study was published in the August 17, 2018, online edition of the journal Cancer Immunology Research.
Related Links:
Brighton and Sussex Medical School
BCG is used in the treatment of superficial forms of bladder cancer. Since the late 1970s, evidence has become available that instillation of BCG into the bladder is an effective form of immunotherapy in this disease. While the mechanism is unclear, it appears a local immune reaction is mounted against the tumor. Immunotherapy with BCG prevents recurrence in up to 67% of cases of superficial bladder cancer. Thus, about 30% of patients experience treatment failure, which cannot be predicted in advance and carries a high risk of disease progression.
Investigators at Brighton and Sussex Medical School (United Kingdom) examined the in vitro tuberculin-responsiveness of CD4+ T cells before BCG immunotherapy in 42 patients with high-risk (non-muscle invasive bladder cancer) NMIBC. The frequencies and functionalities of cytokine-expressing CD4+ T cells immediately before and after BCG immunotherapy induction were assessed by flow cytometry after overnight tuberculin stimulation. Tuberculin-induced secreted mediators were measured by electrochemiluminescence. The results were correlated with recurrence-free patient survival six months after induction.
Results revealed that a tuberculin-induced, secreted, IL2 concentration higher than 250 picograms per milliliter was the best predictor of recurrence-free survival, providing 79% sensitivity, 86% specificity, and overall correct classification in 78.6% of cases. In 50% of patients later experiencing recurrence, but not in any of the recurrence-free survivors, IL2 secretion was less than 120 picograms per milliliter.
Senior author Dr. Florian Kern, professor of immunology at Brighton and Sussex Medical School, said, "The simplicity of our new test makes it very attractive as a clinical test. There are several tests for tuberculosis that are ultimately based on the same test principle and have been rolled out across the world in recent times."
The study was published in the August 17, 2018, online edition of the journal Cancer Immunology Research.
Related Links:
Brighton and Sussex Medical School
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans